DXRX logo
Lab Talks & Webinars

Precision medicine in solid tumors

18 Apr 2024

The first Diaceutics virtual event, “Precision medicine in solid tumors”, will allow you to join the forefront of cancer testing and treatment, beginning with a full day true-to-life virtual event, followed by a series of 8 live webinars. During these events, you’ll get exclusive access to clinical insights from top US lab experts.

Event 6: Navigating Renal Tumor Pathology: Insights and Innovations

April 25th 2024, 3pm EST

precision medicine in solid tumors

A comprehensive exploration of the latest advancements in the pathology of renal tumors. This one-hour webinar will explore the intricacies of renal tumor pathology, focusing on recent developments in the classification of renal tumors, histopathology diagnostic challenges, and emerging trends in the field.

Whether you're a seasoned pathologist, pathology assistant, or medical professional seeking to expand your knowledge, this webinar offers a unique opportunity to stay abreast of cutting-edge advancements in renal tumor pathology.

Precision medicine in solid tumors: Navigating Renal Tumor Pathology: Insights and Innovations
Sign up

Event 7: Unveiling Prostate Cancer: Pathology, Biomarkers, and Treatments

May 16th 2024, 3:00pm EST

Prostate cancer is the most common cancer in men and is second most common cause of cancer deaths. Importantly, the annual rates of prostate cancer incidence continue to rise.

This session will delve into how pathology, genomics and biomarkers guide the management and treatment of prostate cancer and equip you with a comprehensive understanding of this cancer.

Event 9: Cytologic Assessment of Thyroid Nodules in the Era of Precision Medicine: Updates in 2023 Bethesda Reporting System and Diagnostic Challenges/Pitfalls

June 12th 2024, 3pm EST

Fine needle aspiration (FNA) plays a vital role in the evaluation of patients with thyroid nodules, in terms of distinguishing benign, non-neoplastic thyroid nodules that may be conservatively managed from neoplastic or malignant nodules that need surgical intervention. However, a definitive, cytologic diagnosis cannot be rendered in approximately 1/3 thyroid nodules. This session will review updates and challenges associated with assessment of thyroid FNAs.

Previous events:

Precision medicine in solid tumors full day event.

July 18, 2023.

This conference offered an array of thrilling highlights, including:

  • Expert speakers that delved into groundbreaking topics surrounding the treatment of lung cancer, gastric cancer, breast cancer, and digital pathology, delivering the most up-to-date insights and innovative breakthroughs in these areas.
  • Learn about the latest advances in targeted therapies and immunotherapies in a range of indications.
  • Leading laboratory professionals and renowned pathology experts will share their knowledge and experience, providing attendees with invaluable insights into the latest clinical developments and diagnostic techniques which ultimately drive treatment decisions.
  • Witness the transformative impact of digital pathology on tumor analysis and diagnosis. This innovative one-day event provides an opportunity to learn about the cutting-edge technologies and tools employed in this field.
  • Engage in interactive sessions, explore the poster hall, and participate in real-time Q&A sessions with expert speakers. Seize the opportunity to pose your questions and deepen your understanding of these increasingly relevant topics, all hosted on a powerful virtual platform.

Access the virtual space now designed specifically for laboratory professionals, pathologists, and individuals involved in solid tumor diagnostics and treatment. This interactive experience allows you to stay up-to-date with the latest advancements in precision medicine and be part of shaping the future of cancer treatment.

Gynecologic prognostic and predictive markers in the era of precision medicine

October 31, 2023, 12:00pm Eastern Time (US)

Event two in the Precision medicine in solid tumors series aims to review indications for biomarker testing in gynecologic cancers, describe the current prognostic and predictive biomarkers in gynecologic pathology, review guidelines for testing and interpretation of prognostic and predictive biomarkers in gynecologic cancers, and summarize challenges in biomarker testing in gynecologic pathology.

Access the virtual space now designed specifically for laboratory professionals, pathologists, and individuals involved in solid tumor diagnostics and treatment. This interactive experience allows you to stay up-to-date with the latest advancements in precision medicine and be part of shaping the future of cancer treatment.

Revolutionizing Solid Tumor Management: Unleashing the Potential of Liquid Biopsy

30th November 2023, 12:00pm EDT

Join our exclusive webinar, "Revolutionizing Solid Tumor Management: Unleashing the Potential of Liquid Biopsy ," for a comprehensive exploration of the groundbreaking world of liquid biopsy in cancer diagnosis and treatment. This session is your opportunity to delve into the key aspects of liquid genomic profiling and its implications for both pathologists and oncologists.

Small and mighty: The power of FNA and core biopsy for tumor diagnosis and biomarker testing

February 29th 2024, 15:00 EST

In recent years, small volume biopsies have been increasingly utilized for diagnosis of tumors in both primary and recurrent settings. Concomitantly, the numbers of ancillary studies for characterizing tumors and biomarker tests to support appropriate therapy selection are also on the rise. A combination of both cytologic and small histologic samples is often obtained in tandem at time of biopsy. Pathologists are responsible for ensuring judicious selection of specimens appropriate for particular tests in a wide array of tumor types. This session will review optimal small biopsy utilization for diagnosis and ancillary testing in several organ systems.

AI revolution in diagnostic pathology: Is the tide turning?

March 14th 2024, 12:00 EST

The practice of diagnostic pathology has gone through a disruptive transformation in which multiple tools such as digital imaging, advanced artificial intelligence algorithms, and computer-aided diagnostic techniques are resulting in the availability of these new tools to assist, augment and empower the diagnostic pathology. Automated whole slide imaging (WSI) scanners are now rendering diagnostic quality, high-resolution images of entire glass slides and combining these images with innovative digital pathology tools that are making it possible to integrate imaging into all aspects of pathology reporting including anatomical, clinical and molecular pathology. The recent approvals of WSI scanner for primary diagnosis by FDA as well as the approval of prostate AI algorithm has paved the way for starting to incorporate this exciting technology for use in primary diagnosis Once the slides are digitized, artificial intelligence tools are providing a unique platform for innovations and advances in anatomical and clinical pathology workflows. This talk will describe where we are in the journey towards utilizing these digital pathology and AI tools for routine pathology practice and what are the possibilities, once fully implemented.

Precision medicine in solid tumors
Watch recordings